Foghorn Therapeutics
FHTX
59 hedge funds and large institutions have $188M invested in Foghorn Therapeutics in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 9 closing their positions.
16% more capital invested
Capital invested by funds: $163M → $188M (+$25.7M)
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
1.26% more ownership
Funds ownership: 62.73% → 63.98% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 60 → 59 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| 1 |
EC
Euclidean Capital
New York
|
+$2.19M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.95M |
| 3 |
BlackRock
New York
|
+$1.49M |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$790K |
| 5 |
GW
GW & Wade
Wellesley,
Massachusetts
|
+$754K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$949K |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$848K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$750K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$524K |
| 5 |
Millennium Management
New York
|
-$235K |
FHTX Hedge Fund Activity: Q2 2023 in Review
59 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q2 2023, worth a combined $188M — up 16% from $163M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of FHTX and 8 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 17 added.
The largest buyer was Euclidean Capital, adding an estimated $2.19M. The largest seller was Citadel Advisors, exiting entirely with an estimated $949K sold.
- 59 institutional investors held Foghorn Therapeutics (FHTX) as of Q2 2023, down from 60 in Q1 2023.
- Funds reported $188M of Foghorn Therapeutics stock for Q2 2023, up 16% quarter-over-quarter.
- 8 funds opened new Foghorn Therapeutics positions in Q2 2023 and 9 closed out, a net change of -1 holder.
- The largest Foghorn Therapeutics buyer in Q2 2023 was Euclidean Capital, an estimated $2.19M added.
- The largest Foghorn Therapeutics seller in Q2 2023 was Citadel Advisors, an estimated $949K sold.
Based on aggregated 13F filings for Q2 2023.